Table 3 TATI association with clinicopathological characteristics
Total no. of patients | TATI negative (%) | TATI positive (%) | P value | |
|---|---|---|---|---|
Preoperative PSA, ng ml −1 | ||||
<4 | 505 | 485 (96) | 20 (4) | 0.1189 |
4–10 | 1842 | 1742 (94.6) | 100 (5.4) | |
10–20 | 697 | 653 (93.7) | 44 (6.3) | |
>20 | 259 | 251 (96.9) | 8 (3.1) | |
Surgical margin status | ||||
Negative | 2664 | 2527 (94.9) | 137 (5.1) | 0.7693 |
Positive | 662 | 626 (94.6) | 36 (5.4) | |
Gleason score | ||||
⩽3+3 | 1299 | 1229 (94.6) | 70 (5.4) | 0.9482 |
3+4 | 1552 | 1475 (95) | 77 (5.0) | |
4+3 | 387 | 366 (94.6) | 21 (5.4) | |
⩾4+4 | 106 | 101 (95.3) | 5 (4.7) | |
pT stage | ||||
pT2 | 2177 | 2049 (94.1) | 128 (5.9) | 0.0496 |
pT3 | 1132 | 1088 (96.1) | 44 (3.9) | |
pT4 | 40 | 38 (95.0) | 2 (5.0) | |
N stage | ||||
N0 | 1826 | 1740 (95.3) | 86 (4.7) | 0.2054 |
N+ | 141 | 138 (97.9) | 3 (2.1) | |
